文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

IFI16 通过 IL6/PI3K/AKT 轴促进肾透明细胞癌的进展。

IFI16 promotes the progression of clear cell renal cell carcinoma through the IL6/PI3K/AKT axis.

机构信息

Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou, 215000, Jiangsu, China.

Department of Urology, Affiliated Changshu Hospital of Nantong University, Changshu, 215500, Jiangsu, China.

出版信息

J Transl Med. 2024 Jun 3;22(1):533. doi: 10.1186/s12967-024-05354-w.


DOI:10.1186/s12967-024-05354-w
PMID:38831470
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11149187/
Abstract

BACKGROUND: Clear cell renal cell carcinoma (ccRCC) is a common disease in the urinary system, with a high incidence and poor prognosis in advanced stages. Although γ-interferon-inducible protein 16 (IFI16) has been reported to play a role in various tumors, its involvement in ccRCC remains poorly documented, and the molecular mechanisms are not yet clear. METHODS: We conducted bioinformatics analysis to study the expression of IFI16 in ccRCC using public databases. Additionally, we analyzed and validated clinical specimens that we collected. Subsequently, we explored the impact of IFI16 on ccRCC cell proliferation, migration, and invasion through in vitro and in vivo experiments. Furthermore, we predicted downstream molecules and pathways using transcriptome analysis and confirmed them through follow-up experimental validation. RESULTS: IFI16 was significantly upregulated in ccRCC tissue and correlated with poor patient prognosis. In vitro, IFI16 promoted ccRCC cell proliferation, migration, and invasion, while in vivo, it facilitated subcutaneous tumor growth and the formation of lung metastatic foci. Knocking down IFI16 suppressed its oncogenic function. At the molecular level, IFI16 promoted the transcription and translation of IL6, subsequently activating the PI3K/AKT signaling pathway and inducing epithelial-mesenchymal transition (EMT). CONCLUSION: IFI16 induced EMT through the IL6/PI3K/AKT axis, promoting the progression of ccRCC.

摘要

背景:透明细胞肾细胞癌(ccRCC)是泌尿系统常见疾病,晚期发病率高,预后差。虽然γ-干扰素诱导蛋白 16(IFI16)已被报道在各种肿瘤中发挥作用,但它在 ccRCC 中的作用仍知之甚少,其分子机制尚不清楚。

方法:我们使用公共数据库进行生物信息学分析,研究 IFI16 在 ccRCC 中的表达。此外,我们还分析和验证了我们收集的临床标本。随后,我们通过体外和体内实验探讨了 IFI16 对 ccRCC 细胞增殖、迁移和侵袭的影响。此外,我们通过转录组分析预测下游分子和途径,并通过后续实验验证进行确认。

结果:IFI16 在 ccRCC 组织中显著上调,与患者预后不良相关。体外实验表明,IFI16 促进 ccRCC 细胞的增殖、迁移和侵袭,而体内实验则促进皮下肿瘤生长和肺转移灶的形成。敲低 IFI16 抑制了其致癌功能。在分子水平上,IFI16 促进了 IL6 的转录和翻译,随后激活了 PI3K/AKT 信号通路并诱导上皮-间充质转化(EMT)。

结论:IFI16 通过 IL6/PI3K/AKT 轴诱导 EMT,促进 ccRCC 的进展。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55e8/11149187/12936edb998f/12967_2024_5354_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55e8/11149187/0467fbd5c811/12967_2024_5354_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55e8/11149187/219a5f8b417f/12967_2024_5354_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55e8/11149187/5465e11042dd/12967_2024_5354_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55e8/11149187/93a74d8be558/12967_2024_5354_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55e8/11149187/2e4f41909324/12967_2024_5354_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55e8/11149187/7fb6b71e2dbb/12967_2024_5354_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55e8/11149187/a6db4c6ebe95/12967_2024_5354_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55e8/11149187/d62c92675ee8/12967_2024_5354_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55e8/11149187/12936edb998f/12967_2024_5354_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55e8/11149187/0467fbd5c811/12967_2024_5354_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55e8/11149187/219a5f8b417f/12967_2024_5354_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55e8/11149187/5465e11042dd/12967_2024_5354_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55e8/11149187/93a74d8be558/12967_2024_5354_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55e8/11149187/2e4f41909324/12967_2024_5354_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55e8/11149187/7fb6b71e2dbb/12967_2024_5354_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55e8/11149187/a6db4c6ebe95/12967_2024_5354_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55e8/11149187/d62c92675ee8/12967_2024_5354_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55e8/11149187/12936edb998f/12967_2024_5354_Fig9_HTML.jpg

相似文献

[1]
IFI16 promotes the progression of clear cell renal cell carcinoma through the IL6/PI3K/AKT axis.

J Transl Med. 2024-6-3

[2]
PLAUR facilitates the progression of clear cell renal cell carcinoma by activating the PI3K/AKT/mTOR signaling pathway.

PeerJ. 2024

[3]
miR-9-5p/HMMR regulates the tumorigenesis and progression of clear cell renal cell carcinoma through EMT and JAK1/STAT1 signaling pathway.

J Transl Med. 2025-1-9

[4]
Exosomal microRNA-15a from ACHN cells aggravates clear cell renal cell carcinoma via the BTG2/PI3K/AKT axis.

Kaohsiung J Med Sci. 2021-11

[5]
TRIM26 inhibits clear cell renal cell carcinoma progression through destabilizing ETK and thus inactivation of AKT/mTOR signaling.

J Transl Med. 2024-5-21

[6]
The Immunotherapeutic Target ANLN Promotes Renal Clear Cell Carcinoma by Regulating PI3K/Akt and P53 Signaling Pathways.

Biofactors. 2025

[7]
NOP2-mediated 5-methylcytosine modification of APOL1 messenger RNA activates PI3K-Akt and facilitates clear cell renal cell carcinoma progression.

Int J Biol Sci. 2024

[8]
TAF1D promotes tumorigenesis and metastasis by activating PI3K/AKT/mTOR signaling in clear cell renal cell carcinoma.

Cell Signal. 2024-12

[9]
MYBL2 promotes proliferation of clear cell renal cell carcinoma by regulating TOP2A and activating AKT/mTOR signaling pathway.

FASEB J. 2025-1-31

[10]
VHL mutation-mediated SALL4 overexpression promotes tumorigenesis and vascularization of clear cell renal cell carcinoma via Akt/GSK-3β signaling.

J Exp Clin Cancer Res. 2020-6-8

引用本文的文献

[1]
IL1A: a novel prognostic biomarker and potential therapeutic target for renal clear cell carcinoma.

Oncol Res. 2025-6-26

[2]
The dual roles of human PYHIN family proteins in cancer: mechanisms and therapeutic implications.

Front Immunol. 2025-5-2

[3]
DYNC2H1 mutation as a potential predictive biomarker for immune checkpoint inhibitor efficacy in NSCLC and melanoma.

Invest New Drugs. 2025-4

[4]
Critical role of non-coding RNA-mediated ferroptosis in urologic malignancies.

Front Immunol. 2024

[5]
Identification of PI3K-AKT Pathway-Related Genes and Construction of Prognostic Prediction Model for ccRCC.

Cancer Rep (Hoboken). 2024-9

本文引用的文献

[1]
USP12 promotes antiviral responses by deubiquitinating and stabilizing IFI16.

PLoS Pathog. 2023-7

[2]
IFI16/Ifi202 released from breast cancer induces secretion of inflammatory cytokines from macrophages and promotes tumor growth.

J Cell Physiol. 2023-7

[3]
IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC.

Clin Cancer Res. 2023-4-3

[4]
ARPC1B promotes mesenchymal phenotype maintenance and radiotherapy resistance by blocking TRIM21-mediated degradation of IFI16 and HuR in glioma stem cells.

J Exp Clin Cancer Res. 2022-11-16

[5]
Harnessing cytokines and chemokines for cancer therapy.

Nat Rev Clin Oncol. 2022-4

[6]
Metabolic reprogramming in renal cancer: Events of a metabolic disease.

Biochim Biophys Acta Rev Cancer. 2021-8

[7]
Can Be Used as a Biomarker for Diagnosis of Renal Cell Carcinoma and Prediction of Patient Survival.

Front Genet. 2021-2-15

[8]
Cancer Statistics, 2021.

CA Cancer J Clin. 2021-1

[9]
Updates in Staging and Reporting of Genitourinary Malignancies.

Arch Pathol Lab Med. 2020-3

[10]
A panoramic review of IL-6: Structure, pathophysiological roles and inhibitors.

Bioorg Med Chem. 2020-3-1

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索